1094619-69-8

Basic information

• Product Name: (R)-2,2,2-trifluoro-N-(2-(4-oxo-5-(1-phenylpropan-2-yl)-3-(trifluoromethyl)-4,5-dihydroisoxazolo[5,4-d]pyrimidin-6-yl)pyridin-3-yl)acetamide
• Synonyms: (R)-2,2,2-trifluoro-N-(2-(4-oxo-5-(1-phenylpropan-2-yl)-3-(trifluoromethyl)-4,5-dihydroisoxazolo[5,4-d]pyrimidin-6-yl)pyridin-3-yl)acetamide
• CAS NO: 1094619-69-8
• Molecular Weight: 511.383
• Mol File: 1094619-69-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (R)-2,2,2-trifluoro-N-(2-(4-oxo-5-(1-phenylpropan-2-yl)-3-(trifluoromethyl)-4,5-dihydroisoxazolo[5,4-d]pyrimidin-6-yl)pyridin-3-yl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2,2,2-trifluoro-N-(2-(4-oxo-5-(1-phenylpropan-2-yl)-3-(trifluoromethyl)-4,5-dihydroisoxazolo[5,4-d]pyrimidin-6-yl)pyridin-3-yl)acetamide(1094619-69-8)
• EPA Substance Registry System: (R)-2,2,2-trifluoro-N-(2-(4-oxo-5-(1-phenylpropan-2-yl)-3-(trifluoromethyl)-4,5-dihydroisoxazolo[5,4-d]pyrimidin-6-yl)pyridin-3-yl)acetamide(1094619-69-8)

Safety Data

• Hazardous Substances Data: 1094619-69-8(Hazardous Substances Data)

Upstream product

• 200933-25-1 methoxy-(3-nitropyridin-2-yl)-methanol 
• 108655-61-4 methyl 5-amino-3-(trifluoromethyl)isoxazole-4-carboxylate 
• 156-34-3 l-amphetamine 
• 1094619-86-9 (R)-5-amino-N-(1-phenylpropan-2-yl)-3-(trifluoromethyl)isoxazole-4-carboxamide 
• 5470-18-8 2-Chloro-3-nitropyridine 
• 18699-87-1 2-methyl-3-nitropyridine 
• 1094619-88-1 (R)-6-(3-aminopyridin-2-yl)-5-(1-phenylpropan-2-yl)-3-(trifluoromethyl)isoxazolo[5,4-d]pyrimidin-4(5H)-one 
• 407-25-0 trifluoroacetic anhydride 

Relevant articles and documents

THIENO[2,3-D]PYRIMIDIN-4(3H)-ONE, ISOXAZOLO[5,4-D]PYRIMIDIN-4(5H)-ONE AND ISOTHIAZOLO[5,4-D]PYRIMIDIN-4(5H)-ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS

The present invention is directed to novel thieno[2,3-d]pyrimidin-4(3H)-one, isoxazolo[5,4-d]pyrimidin-4(5H)-one and isothiazolo[5,4-d]pyrimidin-4(5H)-one derivatives and pharmaceutically acceptable salts thereof of structural formula (I), wherein the variables R1, R2, R3, X and Z are as described herein. Also provided are pharmaceutical compositions comprising the compounds of formula I as well as methods of treatment employing compounds of formula I to treat a disease or disorder characterized by abnormal bone or mineral homeostasis such as hypoparathyroidism, osteoporosis, osteopenia, periodontal disease, Paget's disease, bone fracture, osteoarthritis, rheumatoid arthritis, and humoral hypercalcemia of malignancy.